MetaCap

Contineum Therapeutics (CTNM) vs PepGen (PEPG)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Contineum Therapeutics (CTNM) has outperformed PepGen (PEPG) over the past year, losing 20.7% versus a loss of 32.0%. PepGen is the larger company by market cap ($356.3 million vs $340.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CTNM-20.69%PEPG-32.01%
+67%-8%-83%
Nov 21, 20251 yearNov 20, 2026
CTNM-43.64%PEPG-68.21%
+63%-17%-98%
Apr 1, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CTNM versus PEPG key metrics
MetricCTNMPEPG
Share price$8.68$3.78
Market cap$340.83M$356.31M
1-day change-3.98%-3.82%
YTD return-24.06%-41.94%
1-year return-20.69%-32.01%
EPS (TTM)$-1.77$-0.77
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-59.98M$-89.66M
52-week high$17.79$7.80
52-week low$6.73$1.31
Distance from 52-week high-51.19%-51.54%
Analyst consensusbuystrong_buy
Avg. price target upside+146.89%+263.76%
Average volume776.03K3.26M
Shares outstanding35.35M94.26M
Employees5153
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CTNM has outperformed PEPG by 11.3 percentage points over the past year.

About Contineum Therapeutics

CTNM stock →

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.

Health Care · Biotechnology: Pharmaceutical Preparations · 51 employees

About PepGen

PEPG stock →

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.

Health Care · Biotechnology: Pharmaceutical Preparations · 53 employees

CTNM vs PEPG FAQ

Which is bigger, Contineum Therapeutics or PepGen?

PepGen (PEPG) is larger, with a market capitalization of $356.31M compared with $340.83M for Contineum Therapeutics (CTNM).

Which stock has performed better over the past year, CTNM or PEPG?

CTNM returned -20.69% over the past 12 months, compared with -32.01% for PEPG (price return, excluding dividends). Past performance does not predict future results.

Are Contineum Therapeutics and PepGen in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons